Investment Rating - The investment rating for the company is "Buy" (maintained) [7] Core Insights - The company reported a revenue of 6.833 billion yuan for 2025, representing a year-on-year growth of 3.48%, while the net profit attributable to the parent company was 888 million yuan, a significant increase of 119.15% [4][7] - The clinical trial technical services business showed signs of recovery, with a revenue of 3.267 billion yuan in 2025, up 2.79% year-on-year, despite a decline in domestic innovative drug clinical operations due to industry cycles [7] - New order prices have stabilized, and net new orders returned to rapid growth, amounting to 10.16 billion yuan in 2025, a year-on-year increase of 20.7% [7] Financial Data and Profit Forecast - Total revenue projections for the company are as follows: 2026E at 7.754 billion yuan, 2027E at 9.109 billion yuan, and 2028E at 11.154 billion yuan, with corresponding year-on-year growth rates of 13.5%, 17.5%, and 22.5% respectively [6] - The net profit attributable to the parent company is forecasted to be 1.177 billion yuan in 2026E, 1.382 billion yuan in 2027E, and 1.735 billion yuan in 2028E, with growth rates of 32.6%, 17.4%, and 25.5% respectively [6] - The company's projected PE ratios are 39 for 2026, 34 for 2027, and 27 for 2028, indicating a favorable valuation compared to peers [7]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights a strong recovery in the biopharmaceutical sector, with significant growth in the "WuXi" companies, indicating a return to a prosperous cycle driven by increased demand and order expansion [4][34] - The report emphasizes the structural growth in the industry, particularly in preclinical services and small molecule CDMO, which are expected to accelerate in 2026 [5][36] Summary by Sections 1. "WuXi" Companies Performance - WuXi AppTec achieved a revenue of 45.46 billion RMB in 2025, a year-on-year increase of 15.8%, with a net profit of 19.15 billion RMB, reflecting a 102.7% increase [13] - WuXi Biologics reported a revenue of 21.79 billion RMB, up 16.7%, and a net profit increase of 45.3% [18] - WuXi STA's revenue grew by 46.7%, with a net profit increase of 69.9%, indicating strong order growth and demand recovery [26] 2. Growth Outlook for 2026 - WuXi AppTec expects a revenue growth of 18-22% for its continuing operations in 2026, with capital expenditures projected to rise to 6.5-7.5 billion RMB [4][35] - WuXi Biologics anticipates a revenue increase of 13-17% in 2026, factoring in currency fluctuations [34] - WuXi STA aims for a CAGR of 30-35% from 2025 to 2030, indicating robust growth potential [34] 3. Structural Growth Trends - The preclinical CRO sector is showing signs of recovery, with WuXi AppTec's testing services returning to positive growth and significant order increases in preclinical services [5][34] - Small molecule CDMO is expected to accelerate growth in 2026, driven by increased demand for GLP-1 class drugs [36] - ADC/XDC/TIDES CDMO sectors are maintaining high growth rates, with WuXi STA projecting a 25% CAGR over the next five years [38] 4. Market Performance - The biopharmaceutical sector rose by 1.56% in March 2026, outperforming the CSI 300 index by 2.97 percentage points [39] - The medical R&D outsourcing sector saw the largest gains, while the blood products sector experienced the most significant decline [40]

Core Viewpoint - The innovation drug sector in China is experiencing significant growth, driven by new drug approvals and favorable policy changes, with a focus on the performance of the ChiNext Innovation Drug ETF. Group 1: Market Performance - The ChiNext Innovation Drug Index rose by 3.42% as of March 17, 2026, with notable increases in constituent stocks such as Sangfor Biopharma (up 9.72%) and Yuandong Biotech (up 7.96%) [1] - The ChiNext Innovation Drug ETF (Huitianfu) increased by 3.23%, reaching a latest price of 0.8 yuan, and has seen a cumulative increase of 1.84% over the past week [1] - The ETF recorded a turnover rate of 3.90% with a trading volume of 19.21 million yuan, and an average daily trading volume of 33.78 million yuan over the past year [1] Group 2: Fund Growth and Inflows - The ChiNext Innovation Drug ETF saw a significant scale increase of 10.69 million yuan over the past two weeks, ranking in the top half among comparable funds [3] - The ETF's share count grew by 39 million shares in the past month, also placing it in the top half of comparable funds [3] - Despite a recent net outflow of 2.30 million yuan, the ETF experienced net inflows on 10 out of the last 15 trading days, totaling 30.51 million yuan [3] Group 3: Company Developments - Rongchang Biopharma's RC288 injection has received acceptance from the NMPA, showcasing promising anti-tumor activity and safety in preclinical studies [3] - Rongchang Biopharma is expected to enter a new growth phase starting in 2026, benefiting from new indications for RC18, RC48, and RC28, along with international sales starting in 2027 [4] - The company anticipates revenue from multiple asset authorizations beginning in 2025, which will enhance its financial statements [4] Group 4: Industry Trends - The new National Basic Medical Insurance Drug List has added 114 new drugs, including 50 innovative drugs, with a negotiation success rate of 88%, indicating a robust market for innovative drugs [5] - The commercialization of innovative drugs is accelerating, supported by improved payment systems and a green channel for insurance access [5] - The CXO industry is highlighted as a strong investment opportunity, with ongoing improvements in global pharmaceutical R&D and increasing collaboration between Chinese companies and multinational corporations [6]

Group 1 - The report indicates that the CXO industry has entered a new growth era driven by innovation and industry prosperity, with significant recovery in performance and orders expected from 2024 onwards [3][6][68] - External disturbances affecting the CXO and upstream industries have marginally improved, with the Federal Reserve expected to start a rate-cutting cycle in September 2024, alongside domestic economic recovery and pharmaceutical industry upgrades [3][18] - The report highlights a clear upward trend in the clinical CRO sector, with leading companies expected to see double-digit growth in new orders by the end of 2025, indicating a definitive industry turning point [3][43] Group 2 - The report emphasizes that the overall supply-demand situation in the industry has improved significantly, marking a clear recovery in industry prosperity [6][68] - The performance of the CDMO sector is expected to rebound, with new molecular tracks such as peptides, ADCs, and small nucleic acids driving industry growth [3][57] - The report suggests focusing on companies with strong core technology advantages and leading positions in their respective segments, such as WuXi AppTec, Kelun Pharmaceutical, and Baiyao Technology [3][68] Group 3 - The report provides forecasts for several companies in the CXO sector, with notable expected net profits for WuXi AppTec at 19.15 billion yuan, representing a 102.65% year-on-year increase [14] - The report notes that the CRO sector is experiencing a recovery in demand, with significant growth in new orders for companies like Tigermed and WuXi AppTec [43][57] - The report highlights the increasing R&D expenditures of the top 20 global pharmaceutical companies, which are projected to reach 168.76 billion USD in 2024, indicating robust demand for CRO services [26][68]

Industry Overview - The pharmaceutical and biotechnology sector experienced a decline of 0.39% last week, ranking 27th among 31 primary industries in the Shenwan index. The CSI 300 index fell by 0.62%, indicating that the pharmaceutical sector outperformed the CSI 300 by 0.23 percentage points [3] - The medical services sub-sector reported a drop of 2.17%, while other sub-sectors such as traditional Chinese medicine and medical commercial showed positive growth [3] Company Performance - Notable performers in the medical services sector included: - Nuohe Zhiyuan (+11.5%) - Xin Licheng (+9.4%) - Dian Diagnostics (+8.2%) - ST Zhongzhu (+7.1%) - Guangzheng Eye Hospital (+6.2%) - Underperformers included: - Boteng Co. (-6.9%) - Chengda Pharmaceutical (-6.6%) - WuXi AppTec (-6.4%) - Mediso (-4.8%) - Chengdu Xian Dao (-4.5%) [4] Financial Metrics - The medical services sector's Price-to-Earnings (PE) ratio is 35.30X, with a one-year maximum of 41.13X and a minimum of 28.46X. The Price-to-Book (PB) ratio stands at 3.58X, with a one-year maximum of 4.00X and a minimum of 2.48X. The PE ratio decreased by 0.85X and the PB ratio decreased by 0.09X compared to the previous week [6] CXO Industry Insights - The J.P. Morgan Healthcare Conference highlighted an optimistic outlook for the CXO industry, with companies like WuXi AppTec and WuXi Biologics showcasing strong growth prospects. The industry is transitioning from scale competition to value competition, focusing on advanced technologies and global supply chains. Notably, ADC CDMO is expected to drive significant revenue growth [7] Investment Recommendations - The report maintains a "buy" rating for the medical services sector, emphasizing the importance of innovation in the pharmaceutical supply chain. Key areas of focus include: - High growth: Companies involved in ADC CDMO and peptide CDMO, such as WuXi AppTec and Hao Yuan Pharmaceutical - Expected improvement: Third-party testing laboratories and consumer healthcare sectors, particularly in ophthalmology and dentistry, such as Aier Eye Hospital and Dian Diagnostics [8]

Summary of the Conference Call on the CRO Industry Industry Overview - The CRO (Contract Research Organization) industry is experiencing a significant improvement in service prices and demand in Q4 2026, reversing the low price and high volume situation seen in the first three quarters of the year, indicating a recovery in the industry's fundamentals [1][5] - The procurement price for experimental monkeys has risen to around 150,000 yuan, with expectations for continued increases in 2026 due to strong global demand and supply shortages [1][6] Key Insights and Arguments - The overall performance of the CRO industry in 2026 is positive, with a notable increase in service prices and demand in Q4, following a challenging first half of the year [2][5] - The demand for overseas CRO services has been strong and is expected to accelerate, driven by improvements in the investment environment and the development of new business pipelines [4][10] - The acquisition of a monkey breeding facility in Cambodia by Charles River may lead to changes in U.S. import policies, potentially exacerbating global supply shortages and increasing procurement costs for experimental monkeys [7] Price Recovery and Market Dynamics - The CRO sector's price recovery in Q4 2026 is primarily driven by the independent and clinical segments, with the former benefiting from new drug development cycles and the latter seeing price increases due to a reduction in the number of CRO companies, which has improved the competitive landscape [1][8] - The clinical pre-stage is driven by improved demand, while the clinical stage is focused on price recovery, with expectations for continued demand growth into 2027 [9] Additional Important Points - The FDA's proposal for organoid alternatives to monkeys is expected to have limited short-term impact on demand, as global demand for monkeys remains high [6] - The overall investment environment for the CRO industry is expected to improve, with emerging business pipelines and optimized competition driving growth opportunities [4][13] - The impact of the biobusiness safety bill on the industry remains uncertain, with potential implications for multinational corporations depending on how the policy evolves [12]

Group 1 - The core viewpoint highlights the significant growth and performance of the Jiashi Science and Technology Medicine ETF, with a turnover rate of 10.94% and a transaction volume of 29.51 million yuan [3] - Over the past three months, the Jiashi Science and Technology Medicine ETF has seen an increase in scale by 45.74 million yuan, indicating substantial growth [3] - In terms of net value, as of October 30, 2025, the ETF has appreciated by 27.50% over the past year, with the highest monthly return since inception reaching 23.29% [3] Group 2 - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.63% of the total index, with leading companies including United Imaging Healthcare and BeiGene [4] - The performance of individual stocks shows varied growth, with notable increases such as 11.02% for Zai Lab and 10.79% for Rongchang Biopharmaceutical [6] Group 3 - The recent launch of the 2025 National Medical Insurance Negotiation introduces a dual-track adjustment model for basic medical insurance and commercial insurance, which is expected to alleviate the payment pressure for high-value innovative drugs [3] - The pharmaceutical sector has experienced a slight pullback, but there is a recovery in the demand for domestic innovative drug research and development, supported by a resurgence in capital market financing and an increase in overseas transactions of innovative drugs [3]

Group 1: Market Performance - The Hong Kong Innovative Drug Selected ETF (520690) increased by 0.22%, with the latest price at 0.89 yuan as of October 29, 2025 [3] - The ETF recorded a turnover of 4.25% during the trading session, with a total transaction value of 21.78 million yuan [3] - Over the past year, the average daily transaction volume of the ETF was 120 million yuan [3] Group 2: Clinical Data and Industry Insights - Grail presented initial data from its multi-cancer early detection product Galleri at the 2025 ESMO annual meeting, showing a positive predictive value of 61.6% and a specificity of 99.6% [3] - Among the detected new cancers, 69.3% were in stages I-III, with a tissue origin accuracy of 91.7% [3] - Guosen Securities views this data as a significant milestone in the multi-cancer early detection field, suggesting Galleri could enhance existing screening systems [3] Group 3: Company Earnings and Trends - Over 280 pharmaceutical and biotech companies, including Heng Rui Pharmaceutical and WuXi AppTec, reported strong Q3 results, driven by advancements in R&D pipelines and new drug launches [3] - The overall industry is exhibiting a positive trend characterized by "innovation as a foundation and overseas expansion" [3] Group 4: CDMO Sector Performance - Lonza, a leading overseas CDMO, reported strong Q3 results, maintaining a revenue growth forecast of 20-21% for the year, with core EBITDA margins between 30-31% [4] - Medpace has seen consecutive growth in new orders for two quarters, indicating a recovering financing environment for U.S. small and mid-sized biotech firms [4] - WuXi AppTec exceeded Q3 performance expectations and raised its full-year guidance, further confirming the positive outlook for the CXO industry [4] Group 5: ETF Size and Inflows - The latest size of the Hong Kong Innovative Drug Selected ETF reached 512 million yuan, marking a new high since its inception [4] - The ETF's share count also hit a record high of 574 million shares [4] - In the past five days, the ETF experienced continuous net inflows, with a peak single-day net inflow of 31.48 million yuan, totaling 82.81 million yuan in net inflows [4]

Core Viewpoint - The innovative drug industry trend remains unchanged, with sufficient adjustments made currently, and it is expected that innovative drugs will rise again after the third quarter reports [1] Group 1: Industry Trends - The CXO sector is performing well, benefiting from potential performance catalysts and high prosperity, with the overseas CXO industry entering a phase of accelerated recovery [1] - There is a clear recovery trend in macro-level BD transactions and mergers and acquisitions, while micro-level new molecular businesses maintain high prosperity [1] - The medical device sector is experiencing a policy turning point, with stock prices, valuations, and allocations at the bottom, and the fundamentals are expected to improve [1] Group 2: Investment Recommendations - It is recommended to focus on innovative drugs, the innovative drug industry chain (export-oriented CXO), and medical devices as the main lines for medium to long-term investment [1] Group 3: ETF Performance - The Guotai Innovation Drug ETF (589720) focuses on innovative drug companies on the Sci-Tech Innovation Board, tracking 30 representative quality companies in the Shanghai Stock Exchange Sci-Tech Innovation Drug Index, primarily featuring high-growth biotech [1] - Since the "924 market" last year, the Sci-Tech Innovation Drug Index has outperformed the Hang Seng Hong Kong Stock Connect Innovative Drug Index, with respective gains of 117.04% and 109.62% during the market rebound period from September 24, 2024, to September 30, 2025 [1] - The Sci-Tech Innovation Drug Index may help better share the elasticity of the Sci-Tech Innovation Board when market risk appetite rebounds [1]

Core Insights - The Hong Kong Medical ETF (159366) and the CSI Hong Kong Stock Connect Medical Theme Index (932069) have shown strong performance, with the index rising by 2.35% and the ETF by 2.42% on the opening day [1] - WuXi AppTec (药明康德) reported significant growth in its Q3 2025 financial results, with a revenue of 12.057 billion yuan, a year-on-year increase of 15.26%, and a net profit of 3.515 billion yuan, reflecting a 53.27% increase [3] - The strong performance of WuXi AppTec is attributed to its core business growth, particularly in the chemical segment, which saw a revenue increase of 29.3% year-on-year [3] Company Performance - WuXi AppTec's Q3 revenue was 12.057 billion yuan, with a net profit of 3.515 billion yuan, and a non-recurring gain of 3.223 billion yuan from the sale of equity in WuXi XDC Cayman Inc. [3] - The chemical business is the main growth driver, with TIDES (peptides and oligonucleotides) revenue reaching 7.84 billion yuan, a remarkable increase of 121.1% year-on-year [3] - The company's core strategy in CRDMO is yielding high growth, with a 17.1% increase in orders in the TIDES sector [3] Industry Trends - The overseas CXO industry is experiencing a recovery, with an increase in BD transactions and M&A activities, indicating a positive trend in global client demand [4] - Leading CXO companies with a global client base and advanced manufacturing capabilities are expected to benefit from this recovery [5] - The top ten weighted stocks in the CSI Hong Kong Stock Connect Medical Theme Index account for 62.95% of the index, highlighting the concentration of investment in key players like WuXi AppTec and JD Health [5]